Research program · Platforms · Intellectual property 3 US Patents filed 5 products

Original contributions

A named
research
program.

3
US Provisional
Patents
2
USPTO
Trademarks
5
Platforms in
portfolio
2
Live in
production
27
DOIs across
repositories

The research program

Governing Adaptive
Clinical Artificial
Intelligence.

Structural failure modes, auditability, and infrastructure for decision safety in real world healthcare environments. A formal theory of externally governed learning systems grounded in peer reviewed empirical audit and deployed production infrastructure.

Pillar 01 · Theory

Externally Governed Learning Systems

Governance modelled as a viability constraint on adaptive computation. Foundation of US Provisional Patent 63/975,551. Published as SSRN 6160268.

Pillar 02 · Audit

Shortcut learning under validation

Empirical validation that shortcut learning and misclassification evade standard validation. Peer reviewed in JAMIA Open, Oxford University Press, January 2026. Harvard GCSRT capstone.

Pillar 03 · Infrastructure

FHIR native governance

Interoperable governance infrastructure on HL7 FHIR. Multi armed bandit based adaptive model selection. Two production instantiations: FxMED OS and DrugSynthAI.

Program paper

Borges, J. Y. V. (2026). Governing Adaptive Clinical Artificial Intelligence: Structural Failure Modes, Auditability, and Infrastructure for Decision Safety (v1.0). Zenodo. 10.5281/zenodo.18472597

Track I · Intellectual property

Three US provisional patents.

Three provisional patent applications filed at the United States Patent and Trademark Office between February and March 2026. All three non provisional conversion deadlines fall within a fifty one day window in early 2027.

Patent 01 · Foundation

Externally Governed Learning Systems

US Provisional 63/975,551. Architectural core of FxMED OS and FxMED Advisor. Originated from Harvard GCSRT thesis. Foundation of the research program.

Patent 02 · Engine

MedBoard AI Adaptive Engine

US Provisional 64/012,574. Three tier Analyst, Strategist, Judge architecture with EGLS governance. Twenty seven claim follow on specification.

Patent 03 · Pipeline

DrugSynthAI Discovery

US Provisional 64/018,624. Three amendments filed. Total fifty one pages. Multi agent pipeline for de novo molecule design targeting genetic disease.

Patent 01 US Provisional 63/975,551
Filed 2026 · 02 · 04
Deadline 2027 · 02 · 04

Externally Governed Learning Systems (EGLS)

Confirmation 9951. Patent Center 74325060. Foundation of the research program and architectural core of the FxMED OS and FxMED Advisor products. Originated from Harvard GCSRT shortcut learning thesis work, published as SSRN 6160268 and Zenodo 10.5281/zenodo.18472595.

Cited as the underlying framework in the MedBoard AI follow on appendix and in the DrugSynthAI governance module.

Patent 02 US Provisional 64/012,574
Filed 2026 · 03 · 21
Deadline 2027 · 03 · 21

MedBoard AI · Adaptive Learning Engine

Confirmation 6954. Patent Center 74992085. Three tier Analyst, Strategist, Judge machine learning architecture with EGLS governance. Covers attention adaptive study prescriptions, recursive self improvement, peer learning, clinical simulation, knowledge graph construction, and career outcome prediction.

Twenty seven claim follow on specification filed 2026 · 03 · 24. USPTO Trademark filed the same day (Serial 99721498, Class 042).

Patent 03 US Provisional 64/018,624
Filed 2026 · 03 · 27
Deadline 2027 · 03 · 27

DrugSynthAI · Governance First Drug Discovery

Confirmation 9061. Patent Center 75043858. Three amendments filed (75043858, 75060417, 75093911). Total fifty one pages. Claim sets A through F. Protection of the multi agent pipeline architecture for de novo molecule design targeting genetically defined disease states.

Dual track: academic research record on SSRN, Zenodo, ChemRxiv, and Research Square; commercial protection through provisional and planned non provisional filings.

Track II · Commercial brands

Two USPTO trademarks.

Brand protection for the two commercial platforms in the FxMEDUS portfolio. Both filings under USPTO Class 042 for software and computing services. Section 1(b) Intent to Use basis.

Trademark 01 · Drug discovery

DrugSynthAI

USPTO Class 042. Brand protection for the governance first drug discovery platform. Filed alongside provisional Patent 03 and Trademark 02 in March 2026.

Trademark 02 · Medical education

MedBoardPRO

USPTO Class 042 · Serial 99721498. Brand protection across medboard.pro, medboardpro.com, and medboardpro.app domains. Harvard inspired design system.

Strategy · Coordinated

Multi domain coverage

Trademarks paired with their corresponding US Provisional Patents and registered domains. Brand layer aligned with patent and platform layers under unified governance.

Trademark 01 DrugSynthAI
USPTO Class 042
Section 1(b) Intent

DrugSynthAI Trademark

Brand protection for the DrugSynthAI governance first drug discovery platform. Filed in USPTO Class 042 covering software as a service for AI assisted molecule design, target identification, and drug candidate evaluation.

Coordinated filing with US Provisional Patent 64/018,624 (DrugSynthAI Discovery) and registered domain drugsynth.ai. Trademark layer protects the commercial brand independent from the underlying patent claims.

Trademark 02 MedBoardPRO
USPTO Serial 99721498
Class 042 · 1(b) Intent

MedBoardPRO Trademark

Filed 2026 · 03 · 24 in USPTO Class 042 under Section 1(b) Intent to Use. Covers software as a service for medical board examination preparation, adaptive learning, and clinical simulation.

Brand protection across medboard.pro, medboardpro.com, and medboardpro.app domains. Coordinated with US Provisional Patent 64/012,574 (MedBoard AI Adaptive Learning Engine) and the Harvard inspired landing page design.

Track III · Production portfolio

Five products, five distinct scopes.

Production and development stage platforms. Two are live in production with public URLs. One is in beta. Two are in earlier development phases under the unified governance framework.

Phase 03 · Live in production

DrugSynthAI · FxMED OS

Two platforms live with public URLs. drugsynth.ai launched 2026 · 03 · 31. fxmed-os.vercel.app in active sprint development.

Phase 02 · Beta

MedBoardPRO

Adaptive licensure preparation engine. Brand launched 2026 · 03 · 21. Eighteen entity Prisma schema, forty five plus API endpoints, sixty one acceptance tests.

Phase 01 · Development

FxMED Advisor · AFMI Platform

FxMED Advisor as second EGLS instantiation, embedded inside FxMED OS. AFMI Platform component extraction reactivated for FxMED OS integration.

Platform 01 Phase 3 · Live
drugsynth.ai
Launched 2026 · 03 · 31

DrugSynthAI

Governance first AI pipeline for de novo molecule design targeting genetically defined mitochondrial defects. Sixty seven autonomous agents across five tiers (eleven pipeline agents, eleven validators, twelve orchestrators, five intelligence agents, eight precision medicine agents) plus fifteen assistants and five specialists. Five hundred thirty six passing tests including thirty seven security tests. One hundred sixty seven API endpoints.

Three validated discovery campaigns complete. One hundred sixty three candidates ranked per campaign. Eighteen stage gate decisions, all passed. Zero kill switch activations. Build discipline under numbered rules R01 to R103.

Revenue tiers: Explorer free, Precision Medicine at 299 dollars per month, Professional at 999 dollars per month, Enterprise on contract. Repository at github.com/fxmedus/drugsynth-ai. AIDD-GOV open standard v0.1 under Apache 2.0.

Platform 02 Phase 3 · Live
fxmed-os.vercel.app
Sprint S29 in progress

FxMED OS · Intelligent Physician Operating System

Clinical operating system for private practices with nineteen complete service layers: patient registry, scheduling, queue flow, encounter management, clinical documents, consent and permissions, attachments and media, portal policy, communications, AI scribe, tenancy, task workflow, entitlements, search, onboarding, white label, proxy access, membership, CRM, and guided setup.

Nine hundred fifteen passing backend tests. One hundred thirty seven passing frontend tests. Forty nine bounded contexts under a monolithic Python application. Four hundred forty canonical patients in production with zero test pollution. ES256 JWT authentication with HS256 legacy fallback.

AI Scribe dormant pending business associate agreement gate. Governance enforced through SOGDR ledger, SIRLP recursive learning protocol, Watcher Protocol, and a formal P0 to P2 fix register.

Platform 03 Phase 2 · Beta
medboard.pro
Brand launch 2026 · 03 · 21

MedBoardPRO · Adaptive Licensure Preparation

Adaptive licensure preparation engine for USMLE and related medical boards. Three tier Analyst, Strategist, Judge machine learning architecture under the EGLS governance framework. Eighteen entity Prisma schema. Forty five plus API endpoints. Seventy eight documented requirements. Sixty one acceptance tests. Full OpenAPI specification.

Harvard inspired landing page. Gold accent design system. Shield logo v6. Brand protection across medboard.pro, medboardpro.com, and medboardpro.app domains. USPTO Trademark MedBoardPRO (Serial 99721498) filed in Class 042 under Section 1(b) Intent to Use.

Platform 04 Phase 1 · In development
Trained AI companion

FxMED Advisor

Clinician trained AI companion. Second production instantiation of externally governed learning systems in the FxMEDUS portfolio, alongside FxMED OS itself. Operates within the EGLS framework and is embedded inside FxMED OS as an operator specific AI layer, distinct from the generic documentation scribe.

Product thesis: inverse of generic large language model wrapped in medical prompts. The companion is trained on the operator specific workflow decisions, communication style, clinical reasoning, and practice preferences. Intellectual property strategy under evaluation: continuation under the EGLS non provisional or separate provisional.

Platform 05 Phase 1 · MVP
Medical education SaaS

AFMI Platform · USMLE Academy

Physician first educational SaaS platform. Technology stack: Next.js 15, FastAPI, Clerk v7 authentication, Supabase, and Stripe billing skeleton. Repository at github.com/fxmedus/afmi-platform.

Component extraction reactivated for FxMED OS integration. Extractable components include the Clerk JWT authentication guard pattern, the Clerk to database webhook upsert pattern, and the multi tenant membership model with tenant scoped request headers.

Track IV · Open source and standards

Public code, public standards.

Selected open source contributions and standards publication. Licensing and contribution policy documented in each repository. Standards published with formal schemas and conformance levels.

Runtime 01 · Operational

MedClaw

Local first multi agent orchestration runtime. Cost aware model routing with Ollama primary and cloud fallback. Powers the broader FxMEDUS engineering workflow.

Standard 01 · Apache 2.0

AIDD-GOV

Artificial Intelligence for Drug Discovery Governance. Open standard with ten formal schemas and three documented conformance levels. Published alongside DrugSynthAI.

Data 01 · CC BY 4.0

Research Data Package

Consolidated data release on Harvard Dataverse supporting the DrugSynthAI research program. Six linked publications, four datasets, M7 manuscript. DOI 10.7910/DVN/WGHUWM.

Open source 01 Operational
Agent orchestration

MedClaw

A local first multi agent orchestration runtime. Cost aware model routing with Ollama as the primary inference path and cloud provider fallback. Access control enforced at the orchestration gateway. Configuration through a structured declaration file. Supports the broader FxMEDUS engineering workflow.

Runtime under launchd management on macOS. Primary model qwen3:8b with deepseek-r1:8b fallback. WebSocket gateway on port 18789 and browser control on port 18791.

Open standard 01 Apache 2.0
Version 0.1

AIDD-GOV

Artificial Intelligence for Drug Discovery Governance. An open standard developed alongside DrugSynthAI and published under Apache 2.0. Ten formal schemas. Three documented conformance levels. Repository at github.com/fxmedus/aidd-gov.

Data release 01 Harvard Dataverse
CC BY 4.0

Consolidated Research Data Package

Consolidated data release supporting the DrugSynthAI research program. Published under Creative Commons Attribution 4.0. Six linked related publications. Four comma separated value datasets, a README, and the M7 manuscript archived. DOI 10.7910/DVN/WGHUWM. Published version two on 2026 · 04 · 09.

V.

Track V · Consolidated IP registry

Filing summary.

Consolidated view of all intellectual property filings by Julian Borges, MD and FxMEDUS, LLC. Three patents, two trademarks. Track indicates whether the asset is tied to published peer reviewed research (academic track), to commercial platform protection only (commercial track), or to both.

Asset Track Application Filed Deadline
EGLS Externally Governed Learning Systems Academic and Commercial 63/975,551 2027 · 02 · 04
MedBoard MedBoard AI · Adaptive Learning Engine Commercial 64/012,574 2027 · 03 · 21
DrugSynth DrugSynthAI · Governance First Drug Discovery Academic and Commercial 64/018,624 2027 · 03 · 27
Trademark DrugSynthAI · USPTO Class 042 Commercial USPTO filed Section 1(b) Intent
Trademark MedBoardPRO · USPTO Class 042 Commercial 99721498 Section 1(b) Intent